Live Online Conference: ICH Q12 Product Life Cycle Management & ICH Q2/ICH Q14 Analytical Procedure Life Cycle Management

Live Online Conference: ICH Q12 Product Life Cycle Management & ICH Q2/ICH Q14 Analytical Procedure Life Cycle Management

Course No 18271



This training/webinar cannot be booked. To find alternative dates for this training/webinar or similar events please see the events list by topic.

For many training courses and webinars, there are also recordings you can order and watch any time. You can find these recordings in a list sorted by topic.

Or simply send us your inquiry by using the following contact form.

* also payable by credit card American Express Visa Mastercard

If you have any questions, please contact us:
Tel.: +49 (0)6221 / 84 44 0 E-Mail:


ICH Q12 Product Life Cycle Management

Dr Rainer Gnibl, GMP Inspector
Dr Ulrich Kissel, Chair of the EQPA
Dr Maren Kopp, Boehringer Ingelheim
Dr Jennifer Maguire, FDA
Dr Lisa Matzen, Boehringer Ingelheim
Luisa Paulo, Hovione
Dr Jean-Louis Robert, ICH Q12 EU topic lead

ICH Q2/ICH Q14 Analytical Procedure Life Cycle Management

Chris Burgess, Burgess Analytical Consultancy Limited
Joachim Ermer, Sanofi-Aventis Deutschland GmbH
Gerald Gellermann, Novartis
Annick Gervais, UCB Pharma
Rainer Gnibl, Local Government of Upper Bavaria
Patrick Jackson, GSK
Luka Kosec,  Agency for Medicinal Products and Medical Devices of the Republic of Slovenia
Jürgen Martin, Martin-Consulting
Xaver Schratt, GBA Pharma
Mijo Stanic, Chromicent



ICH Q12 Product Life Cycle Management

The ICH Q12 topic was endorsed by the ICH Steering Committee in September 2014 and the draft ICH Q12 Guideline on Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management was published for comment  in December 2017. The final ICH Q12 Post-Approval Changes Guideline including two Annexes has been adopted in November 2019. The guideline aims to promote innovation and continual improvement, and strengthen quality assurance and reliable supply of product, including proactive planning of global supply chain adjustments.

The next phase will be the implementation of ICH Q12 across the ICH regions. However, especially in the EU, revision of local regulations (e.g. the EU Variations Regulation) will have to be performed to fully implement the concepts of Q12.

The new guideline has been developed to complement the existing ICH Q8 to Q11 guidelines, especially to enable full realization of more flexible regulatory approaches to post-approval CMC changes. The guideline applies to pharmaceutical drug substances and  products (both chemical and biological). The guideline also applies to drug-device combination products that meet the definition of a pharmaceutical or biological product and to analytical methods.

In order to ensure a standardized approach, the guidance defines the categorization of Post-Approval CMC changes, Established Conditions (ECs), Post-Approval Change Management Protocols (PACMPs), and Product Lifecycle Management (PLCM) concepts. In particular, the guideline emphasizes the relationship between Regulatory Assessment and GMP Inspection.

Furthermore, the guideline describes how ECs are identified as well as what information can be designated as supportive information that would not require a regulatory submission, if changed. Guidance is also included for managing revisions of the ECs over a product’s lifecycle.
Conference presentations, case studies and open discussions will help participants learn more about the lifecycle management of pharmaceutical products and provide a forum for discussing ICH´s new Guideline.

Participants will thus have the opportunity to give feedback and ask questions directly to ICH´s Q12 Expert Working Group (EWG) members on how to move forward with the transition to and implementation of the lifecycle approach.

The meeting will also address topics such as:
  •  What are “Established Conditions” for Manufacture and Control?
  •  How could Postapproval Change Management Protocols look like?
  •  What is the impact of ICH Q12 on analytical method and process validation and transfer?
  •  What are the views and expectations of assessors and inspectors?

ICH Q2/ICH Q14 Analytical Procedure Life Cycle Management
As early as 2018, the ICH announced that the Q2(R2)/Q14 Expert Working Group (EWG) would develop a new ICH quality guideline, ICH Q14, for the development of analytical methods and revise the ICH Q2(R1) guideline for the validation of analytical procedures. This will complement the existing ICH Q8 to Q12 guidance and the current ICH Q13 guidance for continuous manufacturing. The new Analytical Procedure Development Guideline (Q14) will then be relevant for sections S4, P4 and P5 of the CTD and should be seen together with Q8(R2) and Q11 as a supplement to the guidelines. The use of the enhanced approach to analytical procedures development and validation can contribute to resource-efficient drug development as well as submission process or facilitate changes after CMC approval. The revised Q2(R1) guideline will also be relevant for sections S4, P4 and P5 of the CTD, with an emphasis on systematic analytical development. As development and validation are linked and subsequent steps, both guidelines will be worked on by the same Expert Working Group, with a potential to combine both documents into one.

Q2(R1) Revision
The current Q2(R1) „Guideline on Validation of Analytical Procedures: Text and Methodology“ does not yet include modern analytical methods (e.g. near infrared (NIR) spectroscopy or Raman spectroscopy). This gap can lead to insufficient validation data for submissions and thus to additional official queries and thus to a delay in the approval of the application. This applies in particular to methods based on multivariate models, a category for which there is currently no guidance in ICH Q2(R1). NIR or Raman spectroscopy is often used in process control and real-time release testing (RTRT) using multivariate analytical methods. Therefore, the revision of ICH Q2(R1) will specifically serve the validation of modern analytical methods, including a discussion of statistical aspects. Common validation characteristics for methods such as NIR, nuclear magnetic resonance spectroscopy (NMR) and hyphenated techniques such as CE-MS, CE-ICP-MS, LC-NMR, GC-MS, LC-MS will also be considered.

Q14 Analytical Method Development Guide
As there is no ICH guideline for the development of analytical methods yet, it is often the case that applicants only report on analytical validation results and seldom present a performance evaluation with analytical development results. This makes communication with the regulatory authorities more difficult, especially when unconventional analytical methods are used (e.g. RTRT and multivariate models for process control). In addition, the lack of guidelines excludes the possibility for the applicant to provide a scientific basis for flexible regulatory approaches (e.g. Quality by Design (QbD) concept) to change analytical methods after approval.

According to ICH, the new directive is proposed to harmonise the scientific approaches to analytical process development and to provide the principles for the description of the analytical process development process. The new guideline should improve communication between industry and regulators and allow for more efficient, sound scientific and risk-based authorisation and change management for post-authorisation changes to analytical methods.

Issues to be addressed
Q14 Analytical Procedure Development guideline
Main technical and scientific elements, which require harmonization, include:
  • Submission of analytical procedure development and related information in CTD format,
  • The concept and strategy of enhanced approaches for analytical procedures,
  • Performance criteria of analytical procedures,
  • In line with ICH Q8 to ICH Q12, a greater understanding of analytical procedures can create the basis for more efficient, sound science and risked-based lifecycle management (e.g., using analytical QbD (AQbD) principles), 
  • Key elements and terminology,
  • Demonstration of suitability for RTRT.
Q2(R1) Revision
For procedures reliant on multivariate methods the following will be addressed:
  • Definition of validation characteristics applicable to multivariate methods which may differ with the area of application (e.g., identification vs. quantitation, batch vs. continuous process, dosage form assay vs. blending monitoring),
  • Important method parameters (e.g., the number of latent variables) established during method development,
  • Robustness which is well understood, however does not have a quantitative measure,
  • Inclusion of post-approval verification and maintenance considerations as a part of the validation,
  • Requirements for validation data sets.

Target Group

ICH Q12 Product Life Cycle Management

The ECA wishes to actively involve QA personnel dealing with global change management, analytical chemists, QC analysts, R&D scientists, as well as manufacturing scientists (process developers) and managers, and regulatory affairs specialists and regulators.

ICH Q2/ICH Q14 Analytical Procedure Life Cycle Management

This conference is addressed to all persons from
  •  Development
  •  Quality Control
  •  Quality Assurance
  •  Regulatory departments
  •  Contract labs
  •  Authorities
who are involved in the development and validation of analytical procedures or their Evaluation.

Technical Requirements

For our webinars, we use Cisco WebEx, one of the leading suppliers of online meetings. At you can check if your system meets the necessary requirements for the participation at a WebEx meeting and at thesame time install the necessary plug-in. Please just enter your name and email address for the test. If the installation is not possible because of your rights for the computer system, please contact your IT department. WebEx is a standard nowadays and the necessary installation is fast and easy.


ICH Q 12 Product Life Cycle Management
Programme 15 September 2020
09.00 – 09.15 h Welcome and Introduction
09.15 – 10.30 h
Update on ICH Q 12 – Current Status of the Final Document
  • Current status
  • Timelines for Implementation
  • Application of Q12 tools on post approval changes for:
    • Analytical methods
    • Manufacturing process
    • Manufacturing site
10.30 – 10.45 h Coffee Break
10.45 – 11.45 h
Key elements of Lifecycle Management and implications from ICH Q12
  • Quality (and Supply) Risk Management
  • ƒMulti-site Change Management
    • Prioritization, planning, processes and governance
11.45 – 12.15 h Q&A Session 1
12.15 – 13.15 h Lunch
13.15 – 14.15 h
Change Implementation Control now and with ICH Q12
  • How we control change implementation today
  • How will ICH Q12 influence our future?
  • Simplification or new complexity?
  • QP considerations
14.15 – 15.15 h
How Quality Systems have to support the ICH Q12 visionƒ
  • ICH Q10 Pharmaceutical Quality System (PQS)
  • Importance of Quality Metrics
  • Interplay between the PQS and Regulatory Affairs
  • QP experience
15.15 – 15.30 h Coffee Break
15.30 – 16.45 h
Established Conditions Pilot (U.S.)
  • Case studies for process and product
  • Innovative analytic approaches
  • Lessons learned
16.45 – 17.15 h Q&A Session 2

Programme 16 September 2020
08.30 – 09.15 h
How could Postapproval Change Management Protocols (PACMPs) look like?
  • What is a PACMP?
  • Structure
  • Examples
09.15 – 10.00 h
Post-approval CMC Changes - How to Use ICH Q12 effectively
  • Global Regulatory Complexity
  • Agile post-approval change management within ICH Q12 including examples for
    • Classification of changes
    • Established Conditions / PACMPs / PLCM
10.00 – 10.15 h Coffee Break
10.15 – 11.30 h
Views and Expectations of Inspectors
  • Interfaces between ICH Q12 & GMP
  • Intentions, preconditions & the Inspector´s expectations
  • Challenges
11.30 – 12.00 h Q&A Session 3
12.00 h End of conference
ICH Q2/ICH Q14 Analytical Procedure Life Cycle Management
Programme 16 September 2020

13.00 – 13.15 h 
Welcome and Introduction

13.15 – 14.00 h
The Revision of ICH Q2 and Development of ICH Q14
  • Important gaps and deficiencies in current ICH Q2(R1)
  • Content of the draft Guidelines Q2 / Q14
  • Expectations for Q2 revision and  Q14
14.00 – 15.30 h
Product Life Cycle Concept from the Perspective of the Authorities - Focus: New Approaches in Process Development/Validation & Production Routine
  •  Quality by Design Lifecycle
  •  Realtime Release Testing
  •  Modern Process Analysis                             
15.30 – 15.45 h   Break

15.45 – 16.15 h
Description of analytical Procedure and Validation, a Regulator’s View
  •  Development of analytical method vs validation of analytical method
  •  Overall control strategies
16.15 – 16.45 h
How to establish an Analytical Target Profile (ATP) for Small Molecules
  •  What needs an ATP
  •  When to Establish ATPs
  •  How to Write ATPs
  •  How to Use/Update ATPs
16.45 – 17.15 h
How to establish an Analytical Target Profile (ATP) for Large Molecules
  •  ATP as the corner stone of the analytical procedure development strategy
  •  How to set up an ATP for methods applied to biologics
  •  Case studies
17.15 – 18.00 h
Questions & Answers
Programme 17 September 2020

08.30 – 09.00 h
How Software Tools can support QbD Method Development
  •  Modern Quality-by-Design approach
  •  Statistical concepts with experimental design plans (also referred to as Design-of-Experiments) as an efficient and fast tool for method development
  •  Multivariate data analysis software package Fusion QbD®
  •  Chromatography simulation software DryLab®
  •  Workflow and examples in using software packages for method development
09.00 – 09.45 h
The ECA APLM Guide
  •  The ECA Analytical Quality Control Group
  •  Interactions between the Groups within ECA
  •  Drivers for and the process of the guideline development
  •  Contents and structure of version 1 July 2018
  •  Going forward; the journey to version 2
09.45 – 10.00 h  Break

10.00 – 10.45 h
Verifications of Compendial Methods in Pharmaceutical QC
  •  Requirements for verification of compendial methods
  •  Verification versus validation versus analytical transfer
  •  Life cycle approach for compendial methods
  •  Design ranges for compendial methods
  •  Typical verification approaches
10.45 – 11.30 h
Analytical Lifecycle Management using an enhanced versus traditional Approach
  •  ATP, DOE and MODR on a case study
  •  Risk-based approach and patient impact considerations
  •  Analytical method changes post approval
11.30 – 12.00 h
Questions & Answers

12.00 – 13.00 h  Break

13.00 - 13.45 h
Robustness and DoE
  •  Experimental Design
  •  Method Optimisation – Response Surface Designs
  •  Robustness Testing – Fractional Factorial Designs
  •  Ruggedness Testing – Measurement Systems Analysis
  •  Equivalent Testing – Two One Sided Tests
13.45 – 14.30 h
Validation for MAA/NDA. Planning and Execution
  •  Overview of relevant guidelines, pharmacopeial monographs
  •  ICH Q2 current version
  •  Practical Aspects of Method Validation (incl. examples)
14.30 -14.45 h  Break

14.45 – 15.30 h
TMU (Target Measurement Uncertainty)
  •  Stimuli Article by USP
  •  Deriving TMU from Specification
15.30 – 16.15 h
How to establish an efficient and relevant continued Performance Monitoring Program in pharmaceutical Analysis
  •  What method performance information is available? (conformity, validity, numerical performance parameter)
  •  Identification of performance characteristics relevant for the analytical procedure: exploitation of available routine data
  •  Use of control charts
  •  Assay of control batches (virtual and concrete)
  •  The power of multiplicity: Calculation of long-term performance parameters (precisions)
16.15 – 17.00 h
Questions & Answers

Go back

GMP Conferences by Topics